Pay in 4 interest-free payments of $5.04 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
In our modern, fast-paced world, many people struggle with fatigue and low energy, feeling perpetually drained despite efforts to get enough rest, exercise, and nutrition
Cycle 8-12 weeks on, 4-8 weeks off
NEJM.org Journal of the American Medical Association
The SURMOUNT-5 head-to-head trial confirmed tirzepatide outperforms semaglutide by approximately 6 percentage points on average weight loss
Your treatment duration depends on factors such as your overall health, weight loss goals, and response to the medication
Quick Stats for Obesity GLP-1 Market Obesity GLP-1 Market Value (2025): USD 8,169 million Obesity GLP-1 Market Forecast Value (2035): USD 65,364 million Obesity GLP-1 Market Forecast CAGR: 23.1% Leading Molecule Class in Obesity GLP-1 Market: Semaglutide (58.0%) Key Growth Regions in Obesity GLP-1 Market: North America, Europe, and East Asia Top Key Players in Obesity GLP-1 Market: Novo Nordisk, Eli Lilly, and emerging manufacturers Between 2025 and 2030, the obesity GLP-1 market is projected to expand from USD 8169.0 million to USD 39,528 million, resulting in a value increase of USD 31359.0 million, which represents 54.8% of the total forecast growth for the decade
